Trials / Recruiting
RecruitingNCT07121413
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
A Phase IIa, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Shanghai Synvida Biotechnology Co.,Ltd. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, PK and immunogenicity of SV001 in patients with idiopathic pulmonary fibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SV001 | SV001 ： Multiple-dose |
| DRUG | Placebo | Placebo ： Multiple-dose |
Timeline
- Start date
- 2025-11-04
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2025-08-13
- Last updated
- 2026-02-11
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07121413. Inclusion in this directory is not an endorsement.